Mark B. Headley

Mark B. Headley

Auto-generated profile, based on publicly available information

Mark B. Headley

Fred Hutchinson Cancer Center, Seattle, Washington, United States

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2017 in Nature
Verified
Journal Article
Open access
PDF file
ELEmma Lefrançais
Emma Lefrançais
GOGuadalupe Ortiz-Muñoz
Guadalupe Ortiz-Muñoz
ACAxelle Caudrillier
Axelle Caudrillier
BMBeñat Mallavia
Beñat Mallavia
FLFengchun Liu
Fengchun Liu
MLMark R. Looney
Mark R. Looney
Direct imaging of the lung microcirculation in mice indicates that it is a major site of mature platelet production from megakaryocytes. Platelets, which are essential for generating clots to stop bleeding, are produced to a large extent in the bone marrow, but indirect evidence points to a pulmonary contribution to their genesis. Emma Lefrançais et al. imaged microcirculation in the lungs of mice and report that the lung serves as a reservoir for haematopoietic progenitors and platelet-releasing megakaryocytes that can be recruited to compensate for bone marrow deficiencies. They estimate that the lung is responsible for around 50% of total platelet production in mice, a finding that positions it as an organ of notable haematopoietic potential. Platelets are critical for haemostasis, thrombosis, and inflammatory responses1,2, but the events that lead to mature platelet production remain incompletely understood3. The bone marrow has been proposed to be a major site of platelet production, although there is indirect evidence that the lungs might also contribute to platelet biogenesis4,5,6,7. Here, by directly imaging the lung microcirculation in mice8, we show that a large number of megakaryocytes circulate through the lungs, where they dynamically release platelets. Megakaryocytes that release platelets in the lungs originate from extrapulmonary sites such as the bone marrow; we observed large megakaryocytes migrating out of the bone marrow space. The contribution of the lungs to platelet biogenesis is substantial, accounting for approximately 50% of total platelet production or 10 million platelets per hour. Furthermore, we identified populations of mature and immature megakaryocytes along with haematopoietic progenitors in the extravascular spaces of the lungs. Under conditions of thrombocytopenia and relative stem cell deficiency in the bone marrow9, these progenitors can migrate out of the lungs, repopulate the bone marrow, completely reconstitute blood platelet counts, and contribute to multiple haematopoietic lineages. These results identify the lungs as a primary site of terminal platelet production and an organ with considerable haematopoietic potential.

1 August 2016 in Cancer Cell
Verified
Journal Article
Closed access
EREdward W. Roberts
Edward W. Roberts
MBMiranda L. Broz
Miranda L. Broz
MBMikhail Binnewies
Mikhail Binnewies
MHMark B. Headley
Mark B. Headley
ANAmanda E. Nelson
Amanda E. Nelson
MKMatthew F. Krummel
Matthew F. Krummel

14 August 2011 in Nature
Verified
Journal Article
Closed access
PDF file
MSMark C. Siracusa
Mark C. Siracusa
SSSteven A. Saenz
Steven A. Saenz
DHDavid Andrew Hill
David Andrew Hill
BKBrian S. Kim
Brian S. Kim
MHMark B. Headley
Mark B. Headley
DADavid Artis
David Artis

16 March 2016 in Nature
Verified
Journal Article
Closed access
PDF file
MHMark B. Headley
Mark B. Headley
ABAdriaan Bins
Adriaan Bins
ANAlyssa Nip
Alyssa Nip
EREdward W. Roberts
Edward W. Roberts
MLMark R. Looney
Mark R. Looney
MKMatthew F. Krummel
Matthew F. Krummel

1 November 2012 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
HLHai-Chon Lee
Hai-Chon Lee
MHMark B. Headley
Mark B. Headley
YLYueh-Ming Loo
Yueh-Ming Loo
ABAaron Berlin
Aaron Berlin
MGMichael Gale
Michael Gale
SZSteven F. Ziegler
Steven F. Ziegler

23 October 2014 in Blood
Verified
Journal Article
Open access
PDF file
GOGuadalupe Ortiz-Muñoz
Guadalupe Ortiz-Muñoz
BMBeñat Mallavia
Beñat Mallavia
ABAdriaan Bins
Adriaan Bins
MHMark Headley
Mark Headley
MKMatthew F. Krummel
Matthew F. Krummel
MLMark R. Looney
Mark R. Looney
Evidence is emerging that platelets are major contributors to innate immune responses in conditions such as acute lung injury (ALI). Platelets form heterotypic aggregates with neutrophils, and we hypothesized that lipoxin mediators regulate formation of neutrophil-platelet aggregates (NPA) and that NPA significantly contribute to ALI. Lipopolysaccharide (LPS)-induced lung injury was accompanied by platelet sequestration, activation, intra-alveolar accumulation, and NPA formation within both blood and alveolar compartments. Using lung intravital microscopy, we observed the dynamic formation of NPA during physiologic conditions, which sharply increased with ALI. Aspirin (ASA) treatment significantly reduced lung platelet sequestration and activation, NPA formation, and lung injury. ASA treatment increased levels of ASA-triggered lipoxin (ATL; 15-epi-lipoxin A4), and blocking the lipoxin A4 receptor (ALX) with a peptide antagonist (Boc2) or using ALX knockouts (Fpr2/3−/−) reversed this protection. LPS increased NPA formation in vitro, which was reduced by ATL, and engagement of ALX by ATL on both neutrophils and platelets was necessary to prevent aggregation. In a model of transfusion-related acute lung injury (TRALI), Boc2 also reversed ASA protection, and treatment with ATL in both LPS and TRALI models protected from ALI. We conclude that ATL regulates neutrophil-platelet aggregation and that platelet-neutrophil interactions are a therapeutic target in lung injury. Key Points Neutrophil-platelet aggregates are dynamically formed in the lung in response to injury and are regulated by aspirin-triggered lipoxin. The therapeutic effect of aspirin in acute lung injury is in large part mediated by the production of pro-resolving lipid mediators.